URGN•benzinga•
Reported Saturday, UroGen Pharma's UGN-301 Phase 1 Trial Shows Sustained Bladder Exposure And No Dose-Limiting Toxicities In Non-Muscle Invasive Bladder Cancer
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 28, 2025 by benzinga